Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2009-02-04
2011-10-18
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388150, C424S141100, C424S142100
Reexamination Certificate
active
08039596
ABSTRACT:
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.
REFERENCES:
patent: 5262520 (1993-11-01), Plow et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 6242577 (2001-06-01), Ruoslahti et al.
patent: 6737056 (2004-05-01), Presta
patent: 6852318 (2005-02-01), Varner
patent: 7276589 (2007-10-01), Ramakrishnan et al.
patent: 2003/0103978 (2003-06-01), Deshpande et al.
patent: 2005/0069869 (2005-03-01), Ambrosino et al.
patent: 2005/0260210 (2005-11-01), Ramakrishnan et al.
patent: 2006/0008415 (2006-01-01), Kaisheva et al.
patent: 2006/0040325 (2006-02-01), Wu et al.
patent: 2007/0275460 (2007-11-01), Desjarlais et al.
patent: 2009/0081207 (2009-03-01), Menrad et al.
patent: WO 00/42072 (2000-04-01), None
patent: WO 01/04157 (2001-01-01), None
patent: WO2004/056308 (2004-07-01), None
patent: WO2004/089988 (2004-10-01), None
patent: WO2005/056713 (2005-06-01), None
patent: WO 2005/092073 (2005-10-01), None
patent: WO2005/103081 (2005-11-01), None
patent: WO2005/123780 (2005-12-01), None
patent: WO 2007/134876 (2007-11-01), None
patent: WO 2008/060645 (2008-05-01), None
Adams, G., et al., “Monoclonal Antibody Therapy of Cancer,”Nature Biology, 2005, 1147-1157, vol. 23, No. 9.
Clynes, R., et al., “Fc Receptors Are Required in Passive and Active Immunity to Malanoma,”Proc. Natl. Acad. Sci. USA, 1998, 652-656, vol. 95.
Danen, E., et al., “Emergence of α5β1 Fibronectin- and αvβ3 Vitronectin-Receptor Expression in Melanocytic Tumour Progression,”Histopathology, 1994, 249-256.
Drake, C., et al., “Antibodies to β1-Integrins Cause Alterations of Aortic Vasculogenesis, In Vivo,”Developmental Dynamics, 1992, 83-91, vol. 193.
Enaida, H., et al., “Effect of Growth Factors on Expression of Integrin Subtypes in MicroVascular Endothelial Cells Isolated From Bovine Retinas,” Fukushima J. Med. Sci., 1998, 43-52, vol. 44, No. 1.
Jin, H., et al., “Integrins: Roles in Cancer Development and As Treatment Targets,”British Journal of Cancer, 2004, 561-565, vol. 90.
Kim, S., et al., “Regulation of Angiogenesis In Vivo by Ligation of Integrin α5β1 With the Central Cell-Binding Domain of Fibronectin,”American Journal of Pathology, 2000, 1345-1362, vol. 156, No. 4.
Klein, S., et al., “Basic Fibroblast Growsth Factor Modulates Integrin Expression in Microvascular Endothelial Cells,”Molecular Biology of the Cell, 1993, 973-982, vol. 4.
Mousa, S., et al., “Role of Hypoxia and Extracellular Matrix-Integrin Binding in the Modulation of Angiiogenic Growth Factors Secretion by Retinal Pigmented Epithelial Cells,”Journal of Cellular Biochemistry, 1999, 135-143, vol. 74.
Muschler, J., et al., “Down-regulation of the Chicken α5β1Integrin Fibronectin Receptor During Development,”Development, 1991, 327-337, vol. 113.
Newton, S., et al., “Inhibition of Experimental Metastasis of Human Breast Carcinoma Cells in Athymic Nude Mice by anti- α5β1Fibronectin Receptor Integrin Antibodies,”International Journal of Oncology, 1995, 1063-1070, vol. 6.
Presotto, C., et al., “A Novel Muscle Protein Located Inside the Terminal Cisternae of the Sarcoplasmic Reticulum,”The Journal of Biological Chemistry, 1997, 6534-6538, vol. 272, No. 10.
Ravetch, J., et al., “Fc Receptors,”Annu. Rev. Immunol., 1991, 457-492.
Redick, S., et al., “Defining Fibronectin's Cell Adhesion Synergy Site by Site-directed Mutagenesis,”The Journal of Cell Biology, 2000, 521-527, vol. 149, No. 2.
Shields, R.,et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG1 Variants With Improved Binding to the FcyR,”The Journal of Biological Chemistry, 2001, 6591-6604, vol. 276, No. 9.
Shinohara, M., et al., “Expression of Integrins in Squamous Cell Carcinoma of the Oral Cavity,”American Journal of Clinical Pathology, 1999, 75-88, vol. 111.
Takagi, J., et al., “Structure of Integrin α5β1In Complex With Fibronectin,” The EMBO Journal, 2003, 4607-4615, vol. 22, No. 18.
Treon, S., et al., “Polymorphisms in FcyRIIIA (CD 16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström's Macroglobulinemia,”Journal of Clinical Oncology, 2005, 474-481, vol. 23, No. 3.
Trikha, M., et al., “CNTO 95, A Fully Human Monoclonal Antibody That Inhibits αv Integrins, Has Antitumor and Antiangiogenic Acticity In Vivo,”Int. J. Cancer, 2004, 326-335, vol. 110.
Uchida, J., et al., “The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes Through Fc Receptor-dependent Mechanisms During Anti-CD20 Antibody Immunotherapy,”The Journal of Experimental Medicine, 2004, 1659-1669, vol. 199, No. 12.
Yao, M., et al., “Expression of the Integrin α5Subunit and Its Mediated Cell Adhesion in Hepatocellular Carcinoma,” J. Cancer Res. Clin. Oncology, 1997, 435-440, vol. 123.
Ramakrishnan, V. et al., “Preclinical Evaluation of an anti-Alpha5betal Integrin Antibody As a Novel Anti-Angiogenic Agent”,Journal of Experimental Therapeutics and Oncology, Rapid Science Publishers, London, GB, vol. 5, May 4, 2006 pp. 273-286.
International Search Report dated Jun. 22, 2009.
Bender Steven Lee
Brams Peter
Casperson Gerald Fries
Chen Haibin
Devaux Brigitte
Bristol--Myers Squibb Company
Dickstein & Shapiro LLP
Gussow Anne M.
Pfizer Inc.
LandOfFree
Alpha 5-beta 1 antibodies and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha 5-beta 1 antibodies and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha 5-beta 1 antibodies and their uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4285028